Filling the need for trusted information on national health issues

MSF Releases New Report On DR-TB Treatment, Urges Company To Halve Price Of Newer TB Drug Bedaquiline

Médecins Sans Frontières: High prices restrict access to best drug-resistant tuberculosis treatment
“People with drug-resistant tuberculosis (DR-TB) continue to be deprived of today’s best-possible treatment in part because of high drug prices, according to a new report — DR-TB Drugs Under the Microscope — released [Tuesday] by Médecins Sans Frontières (MSF) at the 49th Union World Conference on Lung Health in The Hague. MSF is calling, in particular, on U.S. pharmaceutical corporation Johnson & Johnson (J&J) to cut the price of the newer TB drug bedaquiline in half, so more lives can be saved…” (10/23).